Si Huan Medical Jumps Over 10% to Reach a New High of HK$1.58, with Subsidiary Company's Injectable Peptide Product Gaining NMPA Approval
August 18, Gralon Daily | Si Huan Medical (0460.HK) rose sharply during trading hours, surpassing 10% to reach a new high of HK$1.58 since February 2022.
According to market information, Si Huan Medical announced that its subsidiary company, Huixi Biological Products Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for the listing application of injectable peptide product Meiglu, which is used to improve blood sugar control in adult patients with type 2 diabetes. Additionally, Meiglu's indication for weight loss has completed its Phase III clinical trial and is currently in the follow-up phase.
It is noted that as the only domestic biological pharmaceutical company that has achieved full product coverage in the field of diabetes and related diseases, Huixi Biological Products' product matrix has formed a significant competitive advantage. Apart from Meiglu's several pipeline products under development, the company has nearly 20 approved diabetes-related drug products, with the richness of its research and development pipeline providing a solid foundation for its long-term development.